-
1 Comment
REYON Pharmaceutical Co., Ltd is currently in a long term uptrend where the price is trading 188.0% above its 200 day moving average.
From a valuation standpoint, the stock is 74.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.2.
REYON Pharmaceutical Co., Ltd's total revenue rose by 0.9% to $33B since the same quarter in the previous year.
Its net income has increased by 251.1% to $2B since the same quarter in the previous year.
Finally, its free cash flow fell by 90.8% to $-16B since the same quarter in the previous year.
Based on the above factors, REYON Pharmaceutical Co., Ltd gets an overall score of 4/5.
| ISIN | KR7102460003 |
|---|---|
| Exchange | KO |
| CurrencyCode | KRW |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | 200B |
|---|---|
| Beta | 0.77 |
| PE Ratio | None |
| Target Price | None |
| Dividend Yield | None |
REYON Pharmaceutical Co., Ltd. manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough and cold remedies; cardiac stimulant; genitourinary smooth muscle relaxants; hemostatics; immunosuppressants; rheumatoid arthritis; local anesthetics; migraine drugs; miscellaneous cardiovascular system drugs; neuromuscular disorder related drugs; nootropics and neurotonics; NSAIDs; respiratory stimulants; skeletal muscle relaxants; and vasodilators. It also develops VM202RY, a vascular neurological disease, etc. gene therapy drug, which is in Phase II clinical trial to treat coronary artery disease, chronic non-healing diabetic/ischemic ulcers, diabetic neuropathy, and amyotrophic lateral sclerosis; VM206RY, anti-cancer gene therapy, which is under Phase I clinical trials for treatment of breast cancer; RY103 [NS101], therapeutics antibody for Alzheimer; and RY104, a gene therapy to treat age-related macular degeneration, as well as BIO-101, a HBV gene vaccine, which is in preclinical studies for hepatitis B; RY105, gene therapy to treat liver fibrosis; GB102, for treatment of chronic kidney and coronary artery disease; RY110 which is an iPSC-derived NK cell therapy for solid tumors; RY108, an antifungal drug which is under preclinical study. In addition, the company engages in the research of RY106/RY107, a mRNA-based virus vaccine and gene therapy for anti-virus and rare genetic diseases; and RY109 which is a pDNA-based cancer vaccine for treatment of Ovarian cancer. REYON Pharmaceutical Co., Ltd. was founded in 1955 and is headquartered in Seoul, South Korea.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 102460.KO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
